Depression by the Response to Antidepressant Drugs C

Total Page:16

File Type:pdf, Size:1020Kb

Depression by the Response to Antidepressant Drugs C J Med Genet: first published as 10.1136/jmg.8.3.306 on 1 September 1971. Downloaded from Journal of Medical Genetics (1971). 8, 306. Differentiation of Two Genetically Specific Types of Depression by the Response to Antidepressant Drugs C. M. B. PARE and J. W. MACK From St Bartholomew's Hospital, London The inability to separate depressive illnesses into TABLE II distinct entities re- INCONSISTENCY OF RESPONSES OF DEPRESSED homogeneous seriously hampers PATIENTS TO TWO DRUGS FROM DIFFERENT search into their aetiology and treatment. This PHARMACOLOGICAL GROUPS enquiry is aimed at investigating whether depressive illnesses can be classified pharmacogenetically. Tricylic Group A depressed patient may respond dramatically to Improvement No Improvement Total one antidepressant yet be completely resistant to MAO inhibitors: another. However, the patient's response tends I mprovement 5 15 20 No improvement 15 30 45 to be similar to drugs from the same pharmacological Total 20 45 65 group of antidepressants, in contrast to their re- sponse to drugs from a different group. Thus a survey of patients in whom the response to anti- depressants were known because of their inclusion It is suggested that a patient's response to anti- copyright. in 'double-blind' trials revealed 16 and 12 who had depressant drugs depends to a considerable extent received two different drugs of the monoamine oxi- on the fundamental biochemical abnormality of his dase inhibitor or tricycic group respectively illness, and that this in turn depends on the genetic (Table I). It is clear that patients tend to respond type of his depression, one type responding to members of the tricylic group of drugs, another TABLE I to the monoamine oxidase inhibitors. If this is so, SIMILARITY IN RESPONSES OF A DEPRESSED one could predict that first-degree relatives who PATIENT TO TWO DIFFERENT DRUGS BELONGING became depressed should respond to antidepressants http://jmg.bmj.com/ TO THE SAME PHARMACOLOGICAL GROUP in a similar way to the proband. Secondly, these Second Drug correlations should be quite different from the response of proband and first degree relative to Improvement No Improvement Total antidepressants from different groups. Evidence Response to 2 different MAO inhibitors* supporting the first part of this prediction has been First drug: Improvement 9 0 9 published by Pare, Rees, and Sainsbury (1962) and No improvement 0 7 7 Total 9 7 16 by Angst (1961-64). on September 29, 2021 by guest. Protected In the present paper we have re-examined our Response to 2 different drugs of the tricylic groupt First drug: original material (Pare et al, 1962) to test the second Improvement 7 1 8 No improvement 0 4 4 part of the hypothesis and retested the whole hypo- Total 7 5 12 thesis in a new series of subjects. * P = 0 000087. t P = 0-012. Old Material to drugs from the same group in a similar way and in Method. Pare et al (1962) studied 170 depressed contrast to their response to two antidepressants patients whose response to antidepressant drugs was from different groups (Table II) (Pare, 1965). known because of their participation in controlled trials. Similar conclusions were reached by Dally (1960) Enquiries were made for any first-degree relatives of and Daily and Rohde (1961). these patients who might have had a depressive illness and been treated at hospital with antidepressant drugs. Received 23 October 1970. The hospital records of these relatives were studied by 306 J Med Genet: first published as 10.1136/jmg.8.3.306 on 1 September 1971. Downloaded from Differentiation of Two Genetically Specific Types ofDepression by the Response to Antidepressant Drugs 307 TABLE III FAMILY CORRELATIONS OF RESPONSE TO ANTIDEPRESSANTS (From Pare et al, 1962) Case No. Drug Response Relation Drug Response 3 Pheneizine + Sister Phenoxypropazine + Imipramine 13 Phenelzine + Sister 'Parstelin' + 57 Amitriptyline + Father Imipramine + Phenelzine 236 Isocarboxazid Father Phenelzine Imipramine Amitriptyline Brother Imipramine Nialam-ide 243 IsocarboxazidImipramine Sister Imipramine Isocarboxazid 250 Isocarboxazid + Sister Tranylcypromine + Imipramine _ Imipramine 300 Imipramine + Sister Imipramine + TABLE IV RESPONSE OF PATIENTS AND FIRST-DEGREE RELATIVES TO ANTIDEPRESSANT DRUGS FROM THE SAME AND DIFFERENT PHARMACOLOGICAL GROUPS (From Pare et al, 1962) Relatives MAO Inhibitors Tricyclic copyright. Improvement No Improvement Improvement No Improvement Probands MAO Inhibitors: Improvement 3 1 No improvement 3 1 I 3 Tricyclic: Improvement I 2 No improvement 2 3 4 http://jmg.bmj.com/ TABLE V FAMILY CORRELATIONS OF RESPONSE TO ANTIDEPRESSANTS on September 29, 2021 by guest. Protected (From Angst, 1964) Results of Results of Treatment Treatment Individuals In Pairs Total °° NPairos + 0 Total;Toa +++ +0+° 0+°)+ No. of __I~~ Endogenous depression Parents and children 38 1 39 20 1 0 0 21 Sibs 30 10 40 14 1 1 4 20 Distant relations 9 3 12 3 1 1 1 6 Total !77 1 4 91 37 3 2 15 47 00007 Detiression of mixed aetiology Schizo-affective 18 12 30 5 4 4 2| 15 + = Responders; 0 = Non-responders. J Med Genet: first published as 10.1136/jmg.8.3.306 on 1 September 1971. Downloaded from 308 Pare and Mack TABLE VI FAMILY CORRELATIONS OF RESPONSE TO ANTIDEPRESSANTS (Present series) Proband Drug Response Relative Drug Response 1 Imipramine + Brother Imipramine + Parstelin 6 Imipramine + Mother Nortriptyline + Parsteim _ Parstelin 9 Parstelin + Sister Imipramine 11 Imipramine + Daughter Amitriptyline + 17 Imipramine - Daughter Imipramine + ~ Phenelzine 9i7 imuprammeTminr:nminO 4- aister.cit,rT...~ rneneizmePhPn,-17inP 31 Parstelin Mother Parstelin Imipramine 37 Amitriptyline Sister Amitriptyline 40 Imipramine Sister Imipramine 54 Triimipramme Sister Imipramine 61 Imipramine Daughter Desipramine 63 Imipramine Sister Amitriptyline 72 Imipramine Sister Phenelzine r TABLE VII RESPONSE OF PATIENTS AND FIRST-DEGREE RELATIVES TO ANTIDEPRESSANT DRUGS FROM THE SAME AND DIFFERENT PHARMACOLOGICAL GROUPS (Present series) Relatives MAO Inhibitors Tricyclic Improvement No Improvement Improvement No Improvement copyright. MAO Inhibitors Improvement 1 2 No improvement 1 1 Tricyclic Improvement 4 7 1 No improvement 1 1 http://jmg.bmj.com/ one of the authors who was unaware of the probands' Present Series response to treatment. He was able to find 8 relatives Method. Using a similar method to that of Pare (of 7 probands) in whom the diagnosis was reasonably et al (1962), 515 probands were contacted. Thirteen of certain. These relatives had received an antidepressant these had first-degree relatives in whom a blind assess- drug in adequate doses and for an of adequate period ment of medical records and personal interview enabled time, and the notes were sufficient to make an assessment us to make a confident diagnosis of depression and a of the response to the drug. definite assessment of their response to an antide- pressant drug (Table on September 29, 2021 by guest. Protected Results. There were 12 correlations between VI). proband and relative where each had received the same group of drug and in every case the response was similar (p <0001) (Table III). Re-examina- Results. Ten patient/relative pairs, each of tion of the material revealed 10 correlations where whom had received a drug from the same group the proband and first-degree relative received anti- of antidepressants, resulted in 12 correlations. Of depressants from different groups when there was no these 10 were concordant, but because of the high similarity in response (Table IV). success rate of the tricyclic antidepressants this did Angst's material, using only imipramine, is sum- not reach a significance level of 5%. The simi- marized in Table V (Angst, 1964). Forty-seven larity between the response of proband and first pairs of depressed probands and relatives tended to degree relative when they received an antidepres- have a similar response to imipramine (p <0-0007) sant from the same group was, however, in marked compared to proband/relative pairs with depressive contrast to their differing responses when drugs of symptoms of mixed aetiology. different groups were used (Table VII). J Med Genet: first published as 10.1136/jmg.8.3.306 on 1 September 1971. Downloaded from Differentiation of Two Genetically Specific Types ofDepression by the Response to Antidepressant Drugs 309 Discussion But other inherited or acquired personality factors The results support the suggestion that the re- would be expected to modify any such genetic sponse to a particular group of antidepressants is at predisposition and to obscure any simple differentia- least in part genetically determined. Investigations tion in terms of reactive or endogenous depression, with the monoamine oxidase inhibitor, nialamide, as set out above. did not point to a variability in absorption, distribu- tion, metabolism, or excretion of the drug as being Summary different in patients who subsequently responded The response to a particular antidepressant drug or did not respond to the drug (Pare and Jenner, in a first-degree relative who becomes depressed, is 1966). Studies of amine concentrations in the similar to that of the depressed proband. However human brain following administration ofmonoamine there is no similarity of response when antidepres- oxidase inhibitors show a wide scatter, some patients sants of different groups are used. The results only showing a small increase in amine concentra- support the suggestion that there is more than one tions. However, there is no evidence of a bimodal biochemical abnormality which may result in de- distribution suggesting two populations, one of pressive illnesses, and that these are genetically whom might respond clinically and one who would specific. not (Jones et al, 1971). It is suggested that the drug response depends in part on the biochemical We would like to thank the Governors of St. type of depression, that there are at least two types, Bartholomew's Hospital and the Medical Research one responding to the monoamine oxidase inhibi- Council for grants to C.M.B.P.
Recommended publications
  • Summary of Product Characteristics
    Package leaflet: Information for the patient Fluoxetine 20mg Capsules, hard fluoxetine Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again. • If you have further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. •If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. What is in this leaflet 1. What Fluoxetine is and what it is used for 2. What you need to know before you take Fluoxetine 3. How to take Fluoxetine 4. Possible side effects 5. How to store Fluoxetine 6. Contents of the pack and other information 1. What Fluoxetine is and what it is used for The name of your medicine is Fluoxetine 20mg Capsules, hard. It contains the active substance fluoxetine. Fluoxetine belongs to a group of medicines called selective serotonin reuptake inhibitor (SSRI) antidepressants. Fluoxetine can be given to treat the following conditions: Adults: • Major depressive episodes • The symptoms of a condition called obsessive-compulsive disorder (OCD). • The eating disorder bulimia nervosa. This medicine is used alongside psychotherapy for the reduction of binge-eating and purging. Children and adolescents aged 8 years and above: • Moderate to severe major depressive disorder, if the depression does not respond to psychological therapy after 4-6 sessions. Fluoxetine should be offered to a child or young person with moderate to severe major depressive disorder only in combination with psychological therapy.
    [Show full text]
  • Download Download
    J. Pharm. Tech. Res. Management Vol. 8, No. 1 (2020), pp.39–46 Vol. 7 | No. 2 | Nov 2019 Journal of Pharmaceutical Technology Research and Management Journal homepage: https://jptrm.chitkara.edu.in/ Ranitidine Induced Hepatotoxicity: A Review Amit Bandyopadhyay Banerjee1, Manisha Gupta2, Thakur Gurjeet Singh3, Sandeep Arora4 and Onkar Bedi5* Chitkara College of Pharmacy, Chitkara University, Punjab-140401, India [email protected] [email protected] [email protected] [email protected] 5*[email protected] (Corresponding Author) ARTICLE INFORMATION ABSTRACT Received: January 29, 2020 Background: Ranitidine (RAN) is one of the common drugs associated with idiosyncratic Revised: April 08, 2020 adverse drug reactions (IADRs) in humans. It was found to be associated with severe adverse drug Accepted: April 28, 2020 reactions due to the presence of contaminants such as N-Nitrosodimethylamine (NDMA) which Published Online: May 20, 2020 is claimed to be carcinogenic. As a consequence, on April 1, 2020, United States Food and Drug Keywords: Administration (USFDA) had decided to call off all the RAN products from the market. The exact DILI, Ranitidine withdrawal, RAN induced cause of RAN associated idiosyncratic hepatotoxicity is not clear yet. hepatotoxicity Purpose: To summarize and analyze the reason behind the withdrawal of RAN products from the market and whether ranitidine will be available again in future or will FDA withdraw approvals of ranitidine National Drug Authority (NDA) and an abbreviated new drug application (ANDA)? Methods: We performed a systematic PubMed/MEDLINE search of studies investigating the reason behind the withdrawal of RAN products and explored the possible mechanism associated with RAN induced hepatotoxicity.
    [Show full text]
  • Nialamide; SOCIETIES and LECTURES CORRECTION
    414 BRITISH MEDICAL JOURNAL 15 MAY 1971 care, and administration of health services. A. Clements, P. A. Connell, Patricia A. Crawford, G. A. Cupper, M. R. Dean, L. L. Dom- "It is, in short, medicine applied to a group SOCIETIES AND LECTURES bey, D. P. De Bono, J. P. Delamere, Gil- than to an individual patient." The lean P. Duncan, D. B. Dunger, C. E. G. Farqu- rather Br Med J: first published as 10.1136/bmj.2.5758.414 on 15 May 1971. Downloaded from statement adds that it is hoped that the pro- For attending lectures marked * a fee is charged or harson, Pamela C. Fenney, Daphne C. Fielding, a ticket is required. Applications should be made I. R. Fletcher, M. S. Fletcher, Po-Kai Fok, G. J. visional Faculty will be in a position to re- Frost, R. M. Galbraith, Elizabeth A. S. Galvin, first to the institution concerned. D. J. Giraldi, Jenifer I. Glover, B. A. Greenway, ceive applications from those wishing to be- Mary Griffin, J. F. Hamlyn, M. H. Hampton, come founder members later in the year. Monday, 17 May G. P. Harris, P. B. Harvey, A. C. Hillyard, Gillian M. M. Hodge, N. Holmes, Sheilagh M. Further announcements will be made. ABERDEEN UNIVERSITY.-At Medical Buildings, Hope, C. C. Hugh, Joanna E. Ide, Alison Ironside, Foresterhill, 5.30 p.m., dentj centennial lecture Keatley E. James, W. J. Jarrett, Celia A. Jenkins, by Sir Robert Bradlaw: Pigmentation. J. R. Jenner, P. D. Jones, C. L. Kennedy, N. D. Monoamine-oxidase Inhibitors INSTITUTE OF DERMATOLOGY.-4.30 p.m., Mr.
    [Show full text]
  • Ayahuasca Characterization, Metabolism in Humans, And
    Louisiana State University LSU Digital Commons LSU Doctoral Dissertations Graduate School 2012 Ayahuasca characterization, metabolism in humans, and relevance to endogenous N,N- dimethyltryptamines Ethan Hamilton McIlhenny Louisiana State University and Agricultural and Mechanical College, [email protected] Follow this and additional works at: https://digitalcommons.lsu.edu/gradschool_dissertations Part of the Medicine and Health Sciences Commons Recommended Citation McIlhenny, Ethan Hamilton, "Ayahuasca characterization, metabolism in humans, and relevance to endogenous N,N- dimethyltryptamines" (2012). LSU Doctoral Dissertations. 2049. https://digitalcommons.lsu.edu/gradschool_dissertations/2049 This Dissertation is brought to you for free and open access by the Graduate School at LSU Digital Commons. It has been accepted for inclusion in LSU Doctoral Dissertations by an authorized graduate school editor of LSU Digital Commons. For more information, please [email protected]. AYAHUASCA CHARACTERIZATION, METABOLISM IN HUMANS, AND RELEVANCE TO ENDOGENOUS N,N-DIMETHYLTRYPTAMINES A Dissertation Submitted to the Graduate Faculty of the Louisiana State University and School of Veterinary Medicine in partial fulfillment of the requirements for the degree of Doctor of Philosophy in The Interdepartmental Program in Veterinary Medical Sciences through the Department of Comparative Biomedical Sciences by Ethan Hamilton McIlhenny B.A., Skidmore College, 2006 M.S., Tulane University, 2008 August 2012 Acknowledgments Infinite thanks, appreciation, and gratitude to my mother Bonnie, father Chaffe, brother Matthew, grandmothers Virginia and Beverly, and to all my extended family, friends, and loved ones. Without your support and the visionary guidance of my friend and advisor Dr. Steven Barker, none of this work would have been possible. Special thanks to Dr.
    [Show full text]
  • The Neurochemical Consequences of Aromatic L-Amino Acid Decarboxylase Deficiency
    The neurochemical consequences of aromatic L-amino acid decarboxylase deficiency Submitted By: George Francis Gray Allen Department of Molecular Neuroscience UCL Institute of Neurology Queen Square, London Submitted November 2010 Funded by the AADC Research Trust, UK Thesis submitted for the degree of Doctor of Philosophy, University College London (UCL) 1 I, George Allen confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. Signed………………………………………………….Date…………………………… 2 Abstract Aromatic L-amino acid decarboxylase (AADC) catalyses the conversion of 5- hydroxytryptophan (5-HTP) and L-3,4-dihydroxyphenylalanine (L-dopa) to the neurotransmitters serotonin and dopamine respectively. The inherited disorder AADC deficiency leads to a severe deficit of serotonin and dopamine as well as an accumulation of 5-HTP and L-dopa. This thesis investigated the potential role of 5- HTP/L-dopa accumulation in the pathogenesis of AADC deficiency. Treatment of human neuroblastoma cells with L-dopa or dopamine was found to increase intracellular levels of the antioxidant reduced glutathione (GSH). However inhibiting AADC prevented the GSH increase induced by L-dopa. Furthermore dopamine but not L-dopa, increased GSH release from human astrocytoma cells, which do not express AADC activity. GSH release is the first stage of GSH trafficking from astrocytes to neurons. This data indicates dopamine may play a role in controlling brain GSH levels and consequently antioxidant status. The inability of L-dopa to influence GSH concentrations in the absence of AADC or with AADC inhibited indicates GSH trafficking/metabolism may be compromised in AADC deficiency.
    [Show full text]
  • Official Protocol Title: NCT Number: NCT02750761
    Official Protocol Title: A Phase 1, Single-Administration Pharmacokinetic and Safety Study of Oral and IV Tedizolid Phosphate in Hospitalized Subjects 2 to <12 Years Old NCT number: NCT02750761 Document Date: 23-Jun-2017 Tedizolid Phosphate (MK-1986) 1 Protocol TR701-120/MK-1986-013, Amendment 4 THIS PROTOCOL AND ALL OF THE INFORMATION RELATING TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC., WHITEHOUSE STATION, NJ, U.S.A. SPONSOR: Cubist Pharmaceuticals, LLC, A wholly-owned indirect subsidiary of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (hereafter referred to as the Sponsor or Merck) Weystrasse 20, Lucerne 6 Switzerland Protocol-specific Sponsor Contact information can be found in the Investigator Trial File Binder (or equivalent). TITLE: A Phase 1, Single-Administration Pharmacokinetic and Safety Study of Oral and IV Tedizolid Phosphate in Hospitalized Subjects 2 to <12 Years Old IND NUMBER: [106,307 (IV) and 125,076 (Oral Suspension)] EudraCT NUMBER: 2015-004595-29 23-Jun-2017 Confidential 04PPD9 Tedizolid Phosphate (MK-1986) 2 Protocol TR701-120, Amendment 4 SUMMARY OF CHANGES: TR701-120 Amendment 4 PRIMARY REASON(S) FOR THIS AMENDMENT: Section Change Rationale 1.0 Synopsis Updated dose for 6 to <12 years from 5 mg/kg to The dose level for the two age groups was adjusted Methodology; 4mg/kg, dose for 2 to <6 years from 5 mg/kg to 6 based on the results of the first interim analysis of the Investigational mg/kg based on the data from interim safety and safety and pharmacokinetic data.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0011643 A1 Dilisa Et Al
    US 2015 0011643A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0011643 A1 DiLisa et al. (43) Pub. Date: Jan. 8, 2015 (54) TREATMENT OF HEART FAILURE AND (60) Provisional application No. 61/038,230, filed on Mar. ASSOCATED CONDITIONS BY 20, 2008, provisional application No. 61/155,704, ADMINISTRATION OF MONOAMINE filed on Feb. 26, 2009. OXIDASE INHIBITORS (71) Applicants:Nazareno Paolocci, Baltimore, MD Publication Classification (US); Univeristy of Padua, Padova (IT) (51) Int. Cl. (72) Inventors: Fabio DiLisa, Padova (IT): Ning Feng, A63L/38 (2006.01) Baltimore, MD (US); Nina Kaludercic, (52) U.S. Cl. Baltimore, MD (US); Nazareno CPC ..... ... A61 K31/138 (2013.01) Paolocci, Baltimore, MD (US) USPC .......................................................... S14/651 (21) Appl. No.: 14/332,234 (22) Filed: Jul. 15, 2014 (57) ABSTRACT Related U.S. Application Data Administration of monoamine oxidase inhibitors is useful in (63) Continuation of application No. 12/407,739, filed on the prevention and treatment of heart failure and incipient Mar. 19, 2009, now abandoned. heart failure. Patent Application Publication Jan. 8, 2015 Sheet 1 of 2 US 201S/0011643 A1 Figure 1 Sial 8. Sws-L) Cleaved Š Caspase-3 ) Figure . Prevention of caspase-3 productief) fron cardiomyocytes Lapoi) reatment with clorgyi Be. Patent Application Publication Jan. 8, 2015 Sheet 2 of 2 US 201S/0011643 A1 Figure 2 8:38:8 ::::::::8: US 2015/0011643 A1 Jan. 8, 2015 TREATMENT OF HEART FAILURE AND in the art is a variety of MAO inhibitors and their pharmaceu ASSOCATED CONDITIONS BY tically acceptable compositions for administration, in accor ADMINISTRATION OF MONOAMINE dance with the present invention, to mammals including, but OXIDASE INHIBITORS not limited to, humans.
    [Show full text]
  • Attendee Guidelines
    (Temple of Eternal Sound) Attendee Guidelines 1. Introduction 2. Practical Guidelines -Preparation -Contraindications -Food -Clothing -Cleansing -During the Session -Suggested Best Practices -Temple Practices & Ritual Norms -Single Sacrament Sanctuary 3. Code of Ethics 4. Dietary Guidelines 5. Medical Information 6. Attendee Waiver Céu do Som Welcome, Thank you for your interest in our Forest Family Circles, Realisation Retreats and Wisdom Works at the Temple of Céu do Som & Abuelatree Sanctuary. You are endeavouring to participate in what, for us, is one of the most profound and meaningful doorways into the mysteries of the Sacred & Profound. The following pages are practical suggestions outlining our expectations, guidelines and safety measures to ensure harmony for you, for our work and for our community. We seek to uphold a high standard in regards to the safe space of transformation and realisation that may create a positive impact through healing and integration of our participants. The guidelines in this booklet all serve a direct purpose. We ask that each one be approached with due respect. It is not necessary to subscribe to our points of view in order to receive the sacrament. We do not discriminate and find that ultimately it is up to the individual to discover what is true for them. Así Céu do Som PRACTICAL GUIDELINES Preparation for the spiritual study Contraindications (refer to Medical Information section for more details) 1. If you are uncertain about any contraindications or factors please ask. 2. If you have any personal concerns a meeting can be arranged prior in order to discuss. 3. If you are taking any prescription medication, namely antidepressants, antipsychotics or SSRI's please speak to us (Refer to Medical Information section).
    [Show full text]
  • The Use of Animals for Research in the Pharmaceutical Industry
    Chapter 8 The use of animals for research in the pharmaceutical industry The ethics of research involving animals The use of animals for research in the CHAPTER 8 pharmaceutical industry Introduction THE USE OF ANIMALS FOR RESEARCH IN PHARMACEUTICAL INDUSTRY 8.1 The pharmaceutical industry conducts or supports approximately one third of the animal research that is undertaken in the UK. Some of this is basic research that seeks to examine normal biological processes and the nature of disease (see also Chapters 5 and 6). However, most has more specific, applied objectives and concerns the development of new medicines or vaccines, improved diagnosis or better methods of toxicity testing. Since the process of producing medicines has changed significantly over time, we begin with a brief overview of developments from the late 19th century to the present. We then describe the way medicines are currently produced in terms of eight stages. These are: discovery and selection of compounds that could be effective medicines (stages 1 and 2), characterisation of promising candidate medicines (stages 3 and 4), selecting candidate medicines and ensuring their safety (stage 5), clinical studies on humans (stages 6 to 8), and also research carried out to support the medicine once it has been marketed. For each stage we describe the way in which animals are used in the process, and give some examples of specific experiments. As in the case of research described in the previous chapters, welfare implications for the animals involved in pharmaceutical research are as diverse as the types of research and must be considered on a case by case basis.
    [Show full text]
  • Ayahuasca Characterization, Metabolism in Humans, and Relevance to Endogenous N,N-Dimethyltryptamines
    ______________________________________________________________________________________________www.neip.info AYAHUASCA CHARACTERIZATION, METABOLISM IN HUMANS, AND RELEVANCE TO ENDOGENOUS N,N-DIMETHYLTRYPTAMINES A Dissertation Submitted to the Graduate Faculty of the Louisiana State University and School of Veterinary Medicine in partial fulfillment of the requirements for the degree of Doctor of Philosophy in The Interdepartmental Program in Veterinary Medical Sciences through the Department of Comparative Biomedical Sciences by Ethan Hamilton McIlhenny B.A., Skidmore College, 2006 M.S., Tulane University, 2008 August 2012 ______________________________________________________________________________________________www.neip.info Acknowledgments Infinite thanks, appreciation, and gratitude to my mother Bonnie, father Chaffe, brother Matthew, grandmothers Virginia and Beverly, and to all my extended family, friends, and loved ones. Without your support and the visionary guidance of my friend and advisor Dr. Steven Barker, none of this work would have been possible. Special thanks to Dr. Rick Strassman MD and the Cottonwood Research Foundation for helping me find and navigate this path. We acknowledge and are grateful for the collaborative research efforts and dedication of Dr. Jordi Riba and his lab which obtained the human urine and blood samples necessary for the included studies. We wish to dedicate this work to the memory of our friend and colleague, Dr. Manel J. Barbanoj. We acknowledge Dr. Leanna Standish for her diligent work in bringing ayahuasca towards clinical trials and collaborative efforts in supplying our lab with ayahuasca samples. We thank Dr. Dave E. Nichols, Dr. Laurent Micouin and Dr. Simon D. Brandt for generously providing analytical compounds. We thank Connie David, Izabela Lomnicka, Pam Waller and Marian Waguespack for technical support in lab.
    [Show full text]
  • Hydroxylamines and Hydrazines As Surrogates of Sp3 Carbons in Medicinal Chemistry
    Wayne State University Wayne State University Dissertations January 2018 Hydroxylamines And Hydrazines As Surrogates Of Sp3 Carbons In Medicinal Chemistry Sandeep Dhanju Wayne State University, [email protected] Follow this and additional works at: https://digitalcommons.wayne.edu/oa_dissertations Part of the Chemistry Commons Recommended Citation Dhanju, Sandeep, "Hydroxylamines And Hydrazines As Surrogates Of Sp3 Carbons In Medicinal Chemistry" (2018). Wayne State University Dissertations. 2156. https://digitalcommons.wayne.edu/oa_dissertations/2156 This Open Access Dissertation is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in Wayne State University Dissertations by an authorized administrator of DigitalCommons@WayneState. HYDROXYLAMINES AND HYDRAZINES AS SURROGATES OF SP3 CARBONS IN MEDICINAL CHEMISTRY by SANDEEP DHANJU DISSERTATION Submitted to the Graduate School of Wayne State University, Detroit, Michigan in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY 2019 MAJOR: CHEMISTRY (Organic) Approved By: Advisor Date DEDICATION I dedicate my PhD work to my parents Sanubhai Shrestha and Punamaya Dhanju, for their endless love and support. ii ACKNOWLEDGEMENTS First and foremost, I would like to express my sincere gratitude to my Ph.D. advisor Prof. David Crich for his incessant support and guidance for my Ph.D. research work during the past five years in his laboratory. I am grateful and fortunate to be one of his graduate students. His encouragement and motivation drove me to the end of this thesis, and I was able to develop an in-depth knowledge and enthusiasm in the areas of organic chemistry and medicinal chemistry. I would like to extend my gratitude to Prof.
    [Show full text]
  • | Hao Wanat Ha Maria Del Mar Man Unit Minit
    |HAO WANAT HA MARIAUS009731026B2 DEL MAR MAN UNIT MINIT (12 ) United States Patent ( 10 ) Patent No. : US 9 ,731 , 026 B2 Su et al. (45 ) Date of Patent: Aug. 15 , 2017 ( 54 ) NEAT LIQUID PHARMACEUTICAL (58 ) Field of Classification Search FORMULATIONS ??? . .. A61K 8 /02 See application file for complete search history . @( 71) Applicant : Massachusetts Institute of Technology , Cambridge, MA (US ) (56 ) References Cited U . S . PATENT DOCUMENTS @( 72 ) Inventors : Erzheng Su , Cambridge, MA (US ) ; Alexander M . Klibanov , Boston , MA 3 , 800 ,038 A 3 / 1974 Rudel ( US ) 5 ,405 ,617 A 4 / 1995 Gowan 7 , 763 ,653 B2 7 / 2010 Pacheco @( 73 ) Assignee : Massachusetts Institute of 2009/ 0004281 Al * 1 / 2009 Nghiem . .. .. .. .. A61K 9 / 0004 Technology , Cambridge , MA (US ) 424 /490 @( * ) Notice : Subject to any disclaimer , the term of this OTHER PUBLICATIONS patent is extended or adjusted under 35 U . S . C . 154 ( b ) by 0 days . Abbott , et al ., “ Novel solvent properties of choline chloride /urea mixtures " , Chem . Commun . , 1 : 70 - 71 ( 2003 ) . Abbott, et al. , “ Ionic liquid analogues formed from hydrated metal ( 21 ) Appl. No. : 14 / 951, 055 salts ” , Chem . , Eur. J . , 10 : 3769 -74 ( 2004 ) . Bica , et al ., “ Liquid forms of pharmaceutical co -crystals : Exploring (22 ) Filed : Nov . 24 , 2015 the boundaries of salt formation ” , Chem Comm ., 47 ( 8 ) : 2267- 9 ( 2011 ) . (65 ) Prior Publication Data Grodowska , et al. , “ Organic solvents in the pharmaceutical indus US 2016 / 0143848 A1 May 26 , 2016 try ” , Acta Polomine Pharma. , 67 ( 1 ) : 3 - 12 (2010 ) . International Search Report for Corresponding PCT/ US2015 / Related U . S . Application Data 062470 mailed Feb . 3 , 2016 .
    [Show full text]